Lori Lawley
Director Financiero/CFO en LUMOS PHARMA, INC. .
Fortuna: 34 536 $ al 30/04/2024
Cargos activos de Lori Lawley
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
LUMOS PHARMA, INC. | Secretario Corporativo | 01/03/2020 | - |
Director Financiero/CFO | 04/07/2021 | - | |
Comptroller/Controller/Auditor | 01/03/2020 | - |
Historial de carrera de Lori Lawley
Antiguos cargos conocidos de Lori Lawley.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
LUMOS PHARMA, INC. | Comptroller/Controller/Auditor | 26/07/2018 | 01/03/2020 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/10/2014 | 01/04/2015 |
Formación de Lori Lawley.
McCombs School of Business | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Reino Unido | 2 |
2 |
Operativa
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 1 |
Corporate Secretary | 1 |
Sectorial
Health Technology | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
LUMOS PHARMA, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
NewLink Genetics Corp.
NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
- Bolsa de valores
- Insiders
- Lori Lawley
- Experiencia